Literature DB >> 19891019

Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis.

Mitsuteru Kitade1, Hitoshi Yoshiji, Ryuichi Noguchi, Yasuhide Ikenaka, Kosuke Kaji, Yusaku Shirai, Masaharu Yamazaki, Masahito Uemura, Junichi Yamao, Masao Fujimoto, Akira Mitoro, Masahisa Toyohara, Masayoshi Sawai, Motoyuki Yoshida, Chie Morioka, Tatsuhiro Tsujimoto, Hideto Kawaratani, Hiroshi Fukui.   

Abstract

AIM: To elucidate the possible crosstalk between angiogenesis, cytokeratin-18 (CK-18), and insulin resistance (IR) especially in patients with non-alcoholic steatohepatitis (NASH).
METHODS: Twenty-eight patients with NASH and 11 with simple fatty liver disease (FL) were enrolled in this study and underwent clinicopathological examination. The measures of angiogenesis, CK-18, and IR employed were CD34-immunopositive vessels, CK-18-immunopositive cells, and homeostasis model assessment of IR (HOMA-IR), respectively. The correlations of these factors with NASH were elucidated.
RESULTS: Significant development of hepatic neovascularization was observed only in NASH, whereas almost no neovascularization could be observed in FL and healthy liver. The degree of angiogenesis was almost parallel to liver fibrosis development, and both parameters were positively correlated. Similarly, CK-18 expression and HOMA-R were significantly increased in NASH as compared with FL and healthy liver. Furthermore, CK-18 and HOMA-IR were also positively correlated with the degree of neovascularization.
CONCLUSION: These results indicate that the crosstalk between angiogenesis, CK-18, and IR may play an important role in the onset and progression of NASH. 2009 The WJG Press and Baishideng. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19891019      PMCID: PMC2773899          DOI: 10.3748/wjg.15.5193

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.

Authors:  Hitoshi Yoshiji; Shigeki Kuriyama; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Daniel J Hicklin; James Huber; Toshiya Nakatani; Hirohisa Tsujinoue; Koji Yanase; Hiroo Imazu; Hiroshi Fukui
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

2.  CD 34 expression in chronic and neoplastic liver diseases.

Authors:  I Di Carlo; F Fraggetta; R Lombardo; G Azzarello; E Vasquez; S Puleo
Journal:  Panminerva Med       Date:  2002-12       Impact factor: 5.197

3.  Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis.

Authors:  Jesús Medina; Luis Caveda; Paloma Sanz-Cameno; Alicia G Arroyo; Samuel Martín-Vílchez; Pedro L Majano; Luisa García-Buey; Francisco Sánchez-Madrid; Ricardo Moreno-Otero
Journal:  J Hepatol       Date:  2003-05       Impact factor: 25.083

4.  Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis.

Authors:  Mitsuteru Kitade; Hitoshi Yoshiji; Hideyuki Kojima; Yasuhide Ikenaka; Ryuichi Noguchi; Kosuke Kaji; Junichi Yoshii; Koji Yanase; Tadashi Namisaki; Masaharu Yamazaki; Tatsuhiro Tsujimoto; Kei Moriya; Hideto Kawaratani; Takemi Akahane; Hiroshi Fukui
Journal:  Mol Med Rep       Date:  2008 Jul-Aug       Impact factor: 2.952

5.  Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.

Authors:  H Yoshiji; S Kuriyama; J Yoshii; Y Ikenaka; R Noguchi; D J Hicklin; Y Wu; K Yanase; T Namisaki; M Yamazaki; H Tsujinoue; H Imazu; T Masaki; H Fukui
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

6.  Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin.

Authors:  Yoshihiro Kamada; Shinji Tamura; Shinichi Kiso; Hitoshi Matsumoto; Yukiko Saji; Yuichi Yoshida; Koji Fukui; Norikazu Maeda; Hitoshi Nishizawa; Hiroyuki Nagaretani; Yoshihisa Okamoto; Shinji Kihara; Jun-Ichiro Miyagawa; Yasuhisa Shinomura; Tohru Funahashi; Yuji Matsuzawa
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

7.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

8.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

9.  Biological action of leptin as an angiogenic factor.

Authors:  M R Sierra-Honigmann; A K Nath; C Murakami; G García-Cardeña; A Papapetropoulos; W C Sessa; L A Madge; J S Schechner; M B Schwabb; P J Polverini; J R Flores-Riveros
Journal:  Science       Date:  1998-09-11       Impact factor: 47.728

10.  Cytokeratin 8/18 overexpression and complex formation as an indicator of GST-P positive foci transformation into hepatocellular carcinomas.

Authors:  Anna Kakehashi; Masayo Inoue; Min Wei; Shoji Fukushima; Hideki Wanibuchi
Journal:  Toxicol Appl Pharmacol       Date:  2009-05-03       Impact factor: 4.219

View more
  17 in total

Review 1.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

2.  Hepatic fibrosis developing in morbid obesity independent of steatohepatitis: new mechanism or the Rube Goldberg machine?

Authors:  Eric R Kallwitz
Journal:  Hepatol Int       Date:  2012-03-11       Impact factor: 6.047

3.  Angiogenesis: a phenomenon which aggravates chronic liver disease progression.

Authors:  Michał Kukla
Journal:  Hepatol Int       Date:  2012-07-26       Impact factor: 6.047

4.  Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan.

Authors:  Yoshio Sumida; Yuichiro Eguchi; Masafumi Ono
Journal:  World J Hepatol       Date:  2010-10-27

5.  Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.

Authors:  S Lefere; F Van de Velde; L Devisscher; M Bekaert; S Raevens; X Verhelst; Y Van Nieuwenhove; M Praet; A Hoorens; C Van Steenkiste; H Van Vlierberghe; B Lapauw; A Geerts
Journal:  Int J Obes (Lond)       Date:  2017-05-02       Impact factor: 5.095

6.  Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells.

Authors:  Davide Povero; Akiko Eguchi; Ingrid R Niesman; Nektaria Andronikou; Xavier de Mollerat du Jeu; Anny Mulya; Michael Berk; Milos Lazic; Samjana Thapaliya; Maurizio Parola; Hemal H Patel; Ariel E Feldstein
Journal:  Sci Signal       Date:  2013-10-08       Impact factor: 8.192

7.  Histological Characteristics of Non-alcoholic Steatohepatitis in NAFLD Patients With Low Degree of Hepatocyte Apoptosis.

Authors:  Hong-Lei Ma; Kenneth I Zheng; Rafael S Rios; Liang-Jie Tang; Gang Li; Pei-Wu Zhu; Xiao-Dong Wang; Yong-Ping Chen; Ming-Hua Zheng
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

8.  Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.

Authors:  Davide Povero; Akiko Eguchi; Hongying Li; Casey D Johnson; Bettina G Papouchado; Alexander Wree; Karen Messer; Ariel E Feldstein
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

9.  Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.

Authors:  Tadashi Namisaki; Kei Moriya; Mitsuteru Kitade; Kosuke Takeda; Kosuke Kaji; Yasushi Okura; Naotaka Shimozato; Shinya Sato; Norihisa Nishimura; Kenichiro Seki; Hideto Kawaratani; Hiroaki Takaya; Yasuhiko Sawada; Takemi Akahane; Soichiro Saikawa; Keisuke Nakanishi; Takuya Kubo; Masanori Furukawa; Ryuichi Noguchi; Kiyoshi Asada; Koh Kitagawa; Takahiro Ozutsumi; Yuki Tsuji; Daisuke Kaya; Yukihisa Fujinaga; Hitoshi Yoshiji
Journal:  Hepatol Commun       Date:  2017-09-19

10.  Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.

Authors:  Maria-Vasiliki Papageorgiou; Emilia Hadziyannis; Dina Tiniakos; Anastasia Georgiou; Aikaterini Margariti; Athanasios Kostas; George V Papatheodoridis
Journal:  Ann Gastroenterol       Date:  2016-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.